Low-Dose radiation plus immunotherapy shows promise in rectal cancer trial
NCT ID NCT07448142
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for people with a common type of locally advanced rectal cancer. It combines low-dose radiation with an immunotherapy drug (pucotenlimab) and chemotherapy before surgery. The goal is to see if this combination can make the tumor disappear completely, either before or after surgery. About 50 adults will take part, and the study will also track long-term outcomes like cancer recurrence and survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651
RECRUITINGGuangzhou, Guanggong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery